Cargando…

Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications

Kynurenine (Kyn) pathway is a significant metabolic pathway of tryptophan (Trp). The metabolites of the Kyn pathway are closely correlated with numerous diseases. Two main enzymes, indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO or TDO2), regulate the first and rate-limiting st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Zixiang, Yue, Linxiu, Shi, Jiachen, Shao, Mingmei, Wu, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584917/ https://www.ncbi.nlm.nih.gov/pubmed/31258785 http://dx.doi.org/10.7150/jca.31727

Ejemplares similares

On the Non-Redundant Roles of TDO2 and IDO1
por: Puccetti, Paolo
Publicado: (2014)

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
por: Platten, Michael, et al.
Publicado: (2015)

Identification and optimisation of next generation inhibitors of IDO1 and TDO
por: Wise, Alan, et al.
Publicado: (2015)

Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO
por: Kim, Minah, et al.
Publicado: (2021)

Induction of TDO2 and IDO2 in Liver by High-Fat Feeding in Mice: Discrepancies with Human Obesity
por: Poulain-Godefroy, Odile, et al.
Publicado: (2013)

Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn–AhR–AQP4 signaling pathway
por: Du, Lisha, et al.
Publicado: (2020)

Correction: Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn–AhR–AQP4 signaling pathway
por: Du, Lisha, et al.
Publicado: (2021)

IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era
por: Chen, Xiangli, et al.
Publicado: (2020)

Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer
por: Wu, Chunjing, et al.
Publicado: (2023)

Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1
por: Brincks, Erik L., et al.
Publicado: (2020)

Sodium Tanshinone IIA Sulfonate as a Potent IDO1/TDO2 Dual Inhibitor Enhances Anti-PD1 Therapy for Colorectal Cancer in Mice
por: Zhang, Rongjie, et al.
Publicado: (2022)

Preclinical PK investigation of a novel IDO1/TDO dual inhibitor—SHR9146 in mouse plasma and tissues by LC-MS/MS
por: Xiao, Mei, et al.
Publicado: (2023)

TDO Promotes Hepatocellular Carcinoma Progression
por: Li, Shanbao, et al.
Publicado: (2020)

Abnormal metabolic processes involved in the pathogenesis of non-alcoholic fatty liver disease (Review)
por: Shao, Mingmei, et al.
Publicado: (2020)

Pharmacological validation of TDO as a target for Parkinson’s disease
por: Perez‐Pardo, Paula, et al.
Publicado: (2021)

Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening
por: Sari, Suat, et al.
Publicado: (2019)

Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2
por: Tijono, Sofian M, et al.
Publicado: (2022)

Comprehensive Analysis of the Expressionand Prognosis for TDO2 in Breast Cancer
por: Liu, Qiang, et al.
Publicado: (2020)

High levels of TDO2 in relation to pro-inflammatory cytokines in synovium and synovial fluid of patients with osteoarthritis
por: Rong, Genxiang, et al.
Publicado: (2022)

Clinicopathologic features of TDO2 overexpression in renal cell carcinoma
por: Pham, Quoc Thang, et al.
Publicado: (2021)

Wideband TDoA Positioning Exploiting RSS-Based Clustering
por: Fuchs, Andreas, et al.
Publicado: (2023)

TDO2 Promotes the EMT of Hepatocellular Carcinoma Through Kyn-AhR Pathway
por: Li, Lei, et al.
Publicado: (2021)

Identification of potential biomarkers for idiopathic pulmonary fibrosis and validation of TDO2 as a potential therapeutic target
por: Wang, Ru, et al.
Publicado: (2023)

IDO Targeting in Sarcoma: Biological and Clinical Implications
por: Nafia, Imane, et al.
Publicado: (2020)

Pancancer Analysis of Revealed TDO2 as a Biomarker of Prognosis and Immunotherapy
por: Cui, Jing, et al.
Publicado: (2022)

IDO/kynurenine pathway in cancer: possible therapeutic approaches
por: Abd El-Fattah, Eslam E.
Publicado: (2022)

Lysophosphatidic Acid Receptors: Biochemical and Clinical Implications in Different Diseases
por: Xiang, Hongjiao, et al.
Publicado: (2020)

Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses
por: Merlo, Lauren M. F., et al.
Publicado: (2020)

A Novel Experiment-Free Site-Specific TDoA Localization Performance-Evaluation Approach
por: Ye, Xiaokang, et al.
Publicado: (2020)

Analysis and Accuracy Improvement of UWB-TDoA-Based Indoor Positioning System
por: Grasso, Paolo, et al.
Publicado: (2022)

Constitutive TDO2 expression promotes liver cancer progression by an autocrine IL-6 signaling pathway
por: Wu, Zhengzhong, et al.
Publicado: (2021)

TDO2 overexpression correlates with poor prognosis, cancer stemness, and resistance to cetuximab in bladder cancer
por: Pham, Quoc Thang, et al.
Publicado: (2021)

Time Difference of Arrival (TDoA) Localization Combining Weighted Least Squares and Firefly Algorithm
por: Wu, Peng, et al.
Publicado: (2019)

Organ Correlation with Tryptophan Metabolism Obtained by Analyses of TDO-KO and QPRT-KO Mice
por: Shibata, Katsumi, et al.
Publicado: (2016)

Two New Shrinking-Circle Methods for Source Localization Based on TDoA Measurements
por: Luo, Mingzhi, et al.
Publicado: (2018)

Comprehensive behavioral analysis of tryptophan 2,3‐dioxygenase (Tdo2) knockout mice
por: Hattori, Satoko, et al.
Publicado: (2018)

TDO2(+) myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma
por: Hu, Simeng, et al.
Publicado: (2022)

Utilization of Carrier-Frequency Offset Measurements in UWB TDoA Positioning with Receiving Tag
por: Krška, Josef, et al.
Publicado: (2023)

IDO2 in Immunomodulation and Autoimmune Disease
por: Prendergast, George C., et al.
Publicado: (2014)

Impact of IDO1 and IDO2 on the B Cell Immune Response
por: Merlo, Lauren M. F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aacnugmm5tl4ke66slb558nc2v